Emerging vaccine strategies against the incessant pneumococcal disease.

Autor: Duke JA; Sanofi, Suite 300, 2501 Discovery Drive, Orlando, FL, 32826, USA., Avci FY; Department of Biochemistry, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA. favci@emory.edu.
Jazyk: angličtina
Zdroj: NPJ vaccines [NPJ Vaccines] 2023 Aug 17; Vol. 8 (1), pp. 122. Date of Electronic Publication: 2023 Aug 17.
DOI: 10.1038/s41541-023-00715-w
Abstrakt: The incidence of invasive pneumococcal disease (IPD) caused by infection with the pathogen Streptococcus pneumoniae (Spn) has been on a downward trend for decades due to worldwide vaccination programs. Despite the clinical successes observed, the Center for Disease Control (CDC) reports that the continued global burden of S. pneumoniae will be in the millions each year, with a case-fatality rate hovering around 5%. Thus, it is a top priority to continue developing new Spn vaccination strategies to harness immunological insight and increase the magnitude of protection provided. As emphasized by the World Health Organization (WHO), it is also crucial to broaden the implementation of vaccines that are already obtainable in the clinical setting. This review focuses on the immune mechanisms triggered by existing pneumococcal vaccines and provides an overview of the current and upcoming clinical strategies being employed. We highlight the associated challenges of serotype selectivity and using pneumococcal-derived proteins as alternative vaccine antigens.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: